Odyssey Health, Inc.
ODYY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ODYY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ODYY
Odyssey Health, Inc. (ODYY) is a development-stage medical technology company focused on acquiring and developing distinct medical assets, including the CardioMap heart monitoring device and the Save-A-Life choking rescue device, with no current revenue and a history of operating losses.
Key risk: No revenue and limited cash
BioSniper Score
Based on 4 of 6 signals
Financial data as of Apr 30, 2026.
Tracking 5 pipeline candidates for Odyssey Health, Inc..
Odyssey Health, Inc. (ODYY) is a development-stage medical technology company focused on acquiring and developing distinct medical assets, including the CardioMap heart monitoring device and the Save-A-Life choking rescue device, with no current revenue and a history of operating losses.
- Odyssey Health has two technologies in development Didži the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device [sec_mda · as of 2026-06-12].
- The company had cash and equivalents of $0.3M as of 2026-04-30 [sec] and an accumulated deficit of $62.5M as of April 30, 2025 [sec_mda · as of 2025-06-13].
- Odyssey Health reported net income of $0.8M for the period ended 2026-04-30 [sec], but has historically experienced operating losses and negative cash flows [sec_mda · as of 2025-03-14].
- The company is not currently selling or marketing any products, as its products are in development and require FDA clearance or approval to market in the United States [sec_mda · as of 2025-06-13].
- Odyssey Health plans to acquire other technologies and assets and intends to be a trans-disciplinary product development company [sec_mda · as of 2026-06-12].
What works
- The company has two distinct technologies in development (CardioMap and Save-A-Life) that address unmet medical needs [sec_mda · as of 2026-06-12].
- Odyssey Health reported positive net income of $0.8M as of 2026-04-30 [sec], which may indicate improving financial performance.
- The company has a strategy to acquire additional technologies and assets, potentially expanding its pipeline [sec_mda · as of 2026-06-12].
What to weigh
- Odyssey Health has a limited operating history and no revenue from product sales, making it difficult to evaluate its ability to achieve business objectives [sec_mda · as of 2025-10-29].
- The company had an accumulated deficit of $62.5M as of April 30, 2025, and negative shareholders' equity of -$5.3M as of 2026-04-30 [sec_mda · as of 2025-06-13] [sec].
- Cash available of $0.3M as of 2026-04-30 [sec] may be insufficient to fund operations, as the company previously noted cash of $7,187 at January 31, 2025 would not cover operating expenses through the third quarter of fiscal 2025 [sec_mda · as of 2025-03-14].
- The company faces significant competition and rapid technological change, and competitors may develop more advanced or effective products [sec_mda · as of 2025-10-29].
From the filings
Quoted directly from source documents.
Odyssey Health has two technologies in development: CardioMap and Save-A-Life.
“We have two different technologies in development; the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device.”
SEC MD&A · June 12, 2026
The company had an accumulated deficit of $62,493,921 as of April 30, 2025.
“we had an accumulated deficit of $ 62,493,921 as”
SEC MD&A · June 13, 2025
Odyssey Health is not currently selling or marketing any products.
“We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration ("FDA") clearance or approval to market our products will be required to sell in the United States.”
SEC MD&A · June 13, 2025
The company had cash of $7,187 as of January 31, 2025, which was insufficient to meet operating expenses.
“Cash available at January 31, 2025 of $ 7,187 will not provide enough working capital to meet our current operating expenses through the third quarter of fiscal 2025.”
SEC MD&A · March 14, 2025
Risks & what to watch (4)›
Key risks
- No revenue and limited cash — Odyssey Health has no product revenue and cash of $0.3M as of 2026-04-30 [sec], which may be insufficient to fund operations [sec_mda · as of 2025-03-14].
- Regulatory approval uncertainty — Products require FDA clearance or approval, and clinical testing could delay or prevent marketing authorization [sec_mda · as of 2025-10-29].
- Accumulated deficit and negative equity — Accumulated deficit of $62.5M as of April 30, 2025 [sec_mda · as of 2025-06-13] and negative shareholders' equity of -$5.3M as of 2026-04-30 [sec].
- Intense competition — The company faces significant competition in a rapidly changing technological environment [sec_mda · as of 2025-10-29].
What to watch
- Progress of CardioMap and Save-A-Life technologies through development and FDA clearance [sec_mda · as of 2026-06-12].
- Ability to secure additional funding to support operations and product development [sec_mda · as of 2025-10-29].
- Any acquisitions of new technologies or assets as part of the company's business strategy [sec_mda · as of 2026-06-12].
- Changes in cash position and accumulated deficit in future financial reports [sec].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Odyssey Health, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Odyssey Health, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
3.0 months
OCF -$319K · Net income $766K
Lead: Preclinical
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Jun 2024Institutional holders
1
Total value held
$48K
| Holder | Shares | Value |
|---|---|---|
| orleans capital management corp/la | 1,000,000 | $48K |
Frequently asked questions
What is the AI investment thesis for Odyssey Health, Inc.?
Odyssey Health, Inc. (ODYY) is a development-stage medical technology company focused on acquiring and developing distinct medical assets, including the CardioMap heart monitoring device and the Save-A-Life choking rescue device, with no current revenue and a history of operating losses.
What is Odyssey Health, Inc.'s lead drug candidate?
Odyssey Health, Inc.'s most advanced tracked candidate is cardiomap (Preclinical) for heart monitoring and screening.
Who is the CEO of Odyssey Health, Inc.?
Mr. Joseph Michael Redmond is the chief executive officer of Odyssey Health, Inc. (ODYY).
Where is Odyssey Health, Inc. headquartered?
Odyssey Health, Inc. (ODYY) is headquartered in Las Vegas, NV, United States.
What therapeutic areas does Odyssey Health, Inc. focus on?
Odyssey Health, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.